Fig. 4

Validation of MoA models using expression data. Both sJIA vs. control (shown in nodes color) and treated vs. non-treated sJIA patients with canakinumab or tocilizumab expression data (Y-axis and node size) was used to compare model protein values (X-axis). Proteins validated by either sJIA vs. control or treated vs. non-treated expression data are represented by circles and non-validated proteins are represented by crosses. Most of the validated proteins fall in the third quadrant, i.e., their expression is downregulated by the drugs and the MoA model predict downregulation in their activation. The evaluation is represented considering a treated vs. non-treated sJIA patients with canakinumab or tocilizumab (each expression value matched with it corresponding MoA model value), b treated vs. non-treated sJIA patients with canakinumab (each expression value matched with canakinumab MoA model values), and c treated vs. non-treated sJIA patients with tocilizumab (each expression value matched with tocilizumab MoA model values)